The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CA125 kinetics as a potential biomarker of prognosis in nivolumab monotherapy for patients with advanced gastric cancer and peritoneal metastasis.
 
Takayuki Ando
Honoraria - Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED.; Lilly Japan; Merck; Miyarisan pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yosuke Kito
Honoraria - Daiichi Sakyo; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Akira Ueda
Honoraria - Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Iori Motoo
No Relationships to Disclose
 
Ken Ito
No Relationships to Disclose
 
Miho Sakumura
No Relationships to Disclose
 
Yuko Ueda
No Relationships to Disclose
 
Shinya Kajiura
Speakers' Bureau - DAIICHI SANKYO COMPANY, LIMITED; Kyowa Kirin Co., Ltd.; Lilly Japan; Ono Pharmaceutical; Shionogi
 
Naokatsu Nakada
No Relationships to Disclose
 
Koji Nakajima
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kazuaki Harada
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasuyuki Kawamoto
Honoraria - Incyte; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Japan Agency for Medical Research and Development; Takeda
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Ichiro Yasuda
No Relationships to Disclose